Clinical Trials Browser

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Breast Neoplasms, Melanoma

Advanced Breast Cancer

Breast Neoplasms

Multiple Endocrine Neoplasia Type 1

Triple Negative Breast Neoplasms

Advanced HER2+Breast Cancer

Breast Neoplasms

Breast Neoplasms

HER2-positive Metastatic Breast Cancer

Ovarian Neoplasms

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Head and Neck Squamous Cell Cancer

Neoplasm Metastasis

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Breast Neoplasms

Breast Neoplasms

Hormone Receptor Positive Breast Carcinoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Recurrence

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Genetic Diseases, Inborn

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

Breast Neoplasms, Endometrial Neoplasms

Clinical Trials

EPIK-L1

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

EPIK-B5

ALPINIST

EPIK-B3

EPIK-B2

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

TARGET-VM

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

VIKTORIA-1

INAVO121

A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719

GERTRUDE

BYLieve

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

ELEVATE

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

AMEERA-1

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

ASSET

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

SEQUEL-Breast

ALPHABET

SAFIR 03

METALLICA

EMBER